The amount of clinical data reported in January so far is currently 30% below the amount reported during the same month last year, which was the slowest month of 2021.
The value of biopharma deals in 2021 rose above the prior year’s record by about 8%, thanks to an increasing number of high-money transactions. Mergers and acquisitions, however, fell 32% below 2020 as the industry gravitated more toward financings.
RSS
